Nuclear lncRNA NORSF reduces E2 release in granulosa cells by sponging the endogenous small activating RNA miR-339
BMC Biology volume 21, Article number: 221 (2023)
Functioning as a competing endogenous RNA (ceRNA) is the main action mechanism of most cytoplasmic lncRNAs. However, it is not known whether this mechanism of action also exists in the nucleus.
We identified four nuclear lncRNAs that are presented in granulosa cells (GCs) and were differentially expressed during sow follicular atresia. Notably, similar to cytoplasmic lncRNAs, these nuclear lncRNAs also sponge miRNAs in the nucleus of GCs through direct interactions. Furthermore, NORSF (non-coding RNA involved in sow fertility), one of the nuclear lncRNA acts as a ceRNA of miR-339. Thereby, it relieves the regulatory effect of miR-339 on CYP19A1 encoding P450arom, a rate-limiting enzyme for E2 synthesis in GCs. Interestingly, miR-339 acts as a saRNA that activates CYP19A1 transcription and enhances E2 release by GCs through altering histone modifications in the promoter by directly binding to the CYP19A1 promoter. Functionally, NORSF inhibited E2 release by GCs via the miR-339 and CYP19A1 axis.
Our findings highlight an unappreciated mechanism of nuclear lncRNAs and show it acts as a ceRNA, which may be a common lncRNA function in the cytoplasm and nucleus. We also identified a potential endogenous saRNA for improving female fertility and treating female infertility.
In recent decades, non-coding RNAs (ncRNAs) have been the focus of biological research because of their abundance, wide distribution, and strong regulatory functions. Among ncRNAs, microRNAs (miRNAs) and long ncRNAs (lncRNAs) were discovered relatively early, and their mechanisms of action are ireasonably clear [1, 2]. miRNAs generally interact with the 3'-untranslated region (UTR) of target mRNAs, to post-transcriptionally repress mRNAs in the cytoplasm through mRNA decay and translation inhibition by RNA-RNA interactions . Additionally, a few miRNAs in the cytoplasm regulate mRNA stability by interacting with the 5'-UTR of target mRNAs [3, 4]. Interestingly, a systematic analysis of miRNA subcellular distribution has shown that most miRNAs are present in both the nuclear and cytoplasmic compartments , with some miRNAs (e.g., miR-29b and miR-2337) being mainly expressed in the nucleus [6, 7]. However, few studies have focused on miRNAs in the nucleus. Unlike the cytoplasmic miRNAs, miRNAs in the nucleus usually activate target transcription through an RNA activation (RNAa) mechanism [7,8,9,10]. More recently, a report showed that miR-23a in the nucleus induces the transcription of NORHA, a follicular atresia-related lncRNA, by interacting with its promoter via an RNA–DNA interaction mechanism; thereby, it altered the granulosa cells (GCs) response to oxidative stress and controlled female fertility . These results suggest that the mechanism of action of miRNAs is directly related to their subcellular localization (nucleus or cytoplasm).
Similar to miRNAs, subcellular localization is a critical determinant of the functions and mechanisms of lncRNAs . However, unlike miRNAs, the mechanism of action of lncRNAs is more complex and diverse in both the nucleus and cytoplasm [13, 14]. In the nucleus, for instance, lncRNAs control the transcription of targets through recruiting chromatin remodeling factors and transcription factors by forming a DNA-RNA triplex with the enhancers and promoters of targets [15, 16], establishing nuclear structural domains by acting as scaffolds for nuclear complexes . In the cytoplasm, lncRNAs affect the post-translational control of target mRNAs through sponging miRNAs and mRNAs by acting as competing endogenous RNAs (ceRNAs) , recruiting RNA-binding proteins (RBPs) to the 3'-UTRs of target mRNAs , or keeping RBPs away from recognition elements in target mRNAs . In addition, lncRNAs retained in the cytoplasm also mediate protein–protein interactions and influence the nuclear translocation of target proteins [21, 22]. New mechanisms of action of lncRNAs in the nucleus and cytoplasm are being discovered. A recent study has suggested that phase separation is a widely used mechanism of action of lncRNAs .
A ceRNA mechanism between lncRNAs and miRNAs in the cytoplasm was the earliest discovered and most common mechanism of action of lncRNAs. In this study, we noticed an interesting phenomenon that may have been ignored, that is, both lncRNAs and miRNAs are distributed in the nucleus [7, 15]. Therefore, a ceRNA mechanism could exist between lncRNAs and miRNAs in the nucleus. Here, we validated this idea using lncRNAs distributed only in the nucleus (here, this type of lncRNA was defined as nuclear lncRNA).
Identification of nuclear DELs during sow follicular atresia
A total of 228 lncRNAs in sow follicles were identified utilizing our previous RNA-seq data  with a higher criteria (reads ≥ 50 in healthy or early atretic follicles) (Additional file 1: Table S1). Next, prediction of the subcellular localization showed that 98 lncRNAs (42.98%) were discovered to be more abundant in the cytoplasm, 44 (19.30%) in the nucleus, and 86 (37.72%) in the other compartments such as the ribosome, cytosol, and exosome (Additional file 1: Table S2). Interestingly, the predicted subcellular localizations of three cytoplasmic lncRNAs, namely LOC102167901 (also known as NORHA), LOC102157709 (also known as BRE-AS), and LOC102162300 (also known as lnc2300), are consistent with our previous nuclear-cytoplasmic fractionation experiments in sow GCs [24,25,26].
Among the 228 follicular lncRNAs, 19 differentially expressed lncRNAs (DELs) during follicular atresia were identified (Fig. 1a). Of them, 47.37% (9 out of 19) of DELs were predicted to be more abundant in the cytoplasm, and 26.32% (5 out of 19) in the nucleus, 26.32% (5 out of 19) in the other compartments (Fig. 1b). In sow follicles, these five DELs predicted to be predominantly expressed in the nucleus were distributed in somatic cells, including GCs (Additional file 2: Fig. S1). Furthermore, nuclear-cytoplasmic fractionation assays of the five DELs predicted to be predominantly expressed in the nucleus and showed that four DELs, namely LOC100512907, LOC100626841, LOC102164325, and LOC102160522, are localized in the nucleus of sow GCs, and LOC102167708 was distributed in both the nucleus (50.47%) and the cytoplasm (49.52%) (Fig. 1c). These data delineated the nuclear-cytoplasmic distribution profile of lncRNAs in sow follicles, and identified four nuclear lncRNAs that were presented exclusively in the nucleus of sow GCs.
Nuclear lncRNAs direct interact with miRNAs in the nucleus of GCs
To investigate whether the four nuclear lncRNAs act as ceRNAs of miRNAs, putative miRNAs that interact with these nuclear lncRNAs were predicted using the online tool miRDB. Putative miRNA response elements (MREs) of 22, 4, 2, and 2 miRNAs were identified in LOC100512907, LOC100626841, LOC102164325, and LOC102160522 (Additional file 1: Table S3), respectively. Among them, miR-144, miR-378, miR-339, and miR-375 are related to sow ovarian functions [26,27,28,29] (Additional file 2: Fig. S2) and were predicted to have a strong binding ability with LOC100512907, LOC100626841, LOC102164325, and LOC102160522,using RNAhybrid (Fig. 2a; Additional file 2: Fig. S3a, b); therefore, they were selected as the candidate miRNAs for further analysis.
Importantly, subcellular localization assays revealed that these four miRNAs (miR-144, miR-378, miR-339, and miR-375) were distributed in the nucleus of sow GCs (Fig. 2b). To determine whether the four nuclear lncRNAs directly interacted with the four corresponding miRNAs in the nucleus, reporter constructs of lncRNAs were synthesized (Fig. 2c; Additional file 2: Fig. S3c). As expected, the luciferase activity of the reporter constructs of lncRNAs with wild-type MRE motifs, but not the mutated MRE motifs, were altered by the corresponding miRNAs (Fig. 2d; Additional file 2: Fig. S3d), indicating that the four nuclear lncRNAs interact with the corresponding miRNAs via the respective MRE motifs. Furthermore, RNA pull-down experiments performed using biotin-labeled lncRNA antisense-specific probes showed that the MRE motifs in nuclear lncRNAs directly interacted with the corresponding miRNAs in GCs (Fig. 2e). Taken together, these results suggest that nuclear lncRNAs directly interact with miRNAs in the nucleus of sow GCs. We speculated that nuclear lncRNAs may as adopt a ceRNA mechanism to sponge miRNAs in the nucleus, similar to lncRNAs and miRNAs co-located in the cytoplasm.
Nuclear NORSF is an endogenous ceRNA of miR-339 in GCs
Next, we further took LOC102164325 and miR-339 as an example to address the above hypothesis that nuclear lncRNAs could function as ceRNAs to sponge miRNAs in the nucleus of sow GCs, because they have the strongest relative binding activity among the four nuclear lncRNAs and their corresponding miRNAs (Additional file 1: Table S4). Rapid amplification of cDNA ends (RACE) assays showed that the LOC102164325 transcript was 748 bp in length, without canonical polyadenylation signal and polyadenylation tail at the 3′ end, and protein-coding potential (Additional file 2: Fig. S4a–e). Furthermore, LOC102164325 exhibits an evolutionary conservation with human lncRNA LOC124906953, both in sequence (with 75% nucleotide identity in partial sequences) and genome location (between two protein-coding genes PLET1 and NCAM1) (Additional file 2: Fig. S4f–g). Interestingly, LOC102164325 is located in a quantitative trait locus (QTL) for the sow fertility trait (QTL ID: 517) on pig chromosome 9 (Fig. 3a); therefore, we renamed it non-coding RNA involved in sow fertility or NORSF.
In sow GCs, miR-339 levels were significantly increased upon NORSF depletion, but significantly decreased upon NORSF overexpression (Fig. 3b, c), indicating that NORSF may sponge miR-339 in GCs via its MRE1 and MRE3 motifs, combined with luciferase assays (Fig. 2d; Additional file 2: Fig. S3d). In contrast, miR-339 had no inhibitory effect on NORSF expression in GCs (Fig. 3d). In addition, we verified the binding of NORSF and miR-339 by in vivo RNA pull-down assay, which showed that miR-339 was significantly enriched by NORSF in sow GCs in vivo (Fig. 3e). Together with RNA pull-down experiments in vitro (Fig. 2e), our findings suggest that nuclear NORSF acts as a ceRNA to sponge miR-339 in the nucleus of sow GCs in vitro and in vivo.
To confirm this conclusion, we investigated whether nuclear NORSF regulates the expression of the target of miR-339 in GCs. In the nucleus, miRNAs usually activate target transcription by interacting with promoters . Interestingly, when we previously characterized the porcine CYP19A1 promoter, we detected an MRE motif of miR-339 in its PII promoter, which is an ovarian-specific promoter (Fig. 3f). Luciferase assay confirmed that NORSF overexpression reduced CYP19A1 transcriptional activity activated by miR-339 (Fig. 3g). Furthermore, miR-339 reversed the reduction of CYP19A1 levels caused by NORSF overexpression (Fig. 3h, i; Additional file 2: Fig. S5a–d). Collectively, these results support the observation that nuclear NORSF acts as a ceRNA to competently bind miR-339 to the CYP19A1 promoter in GCs.
miR-339 acts as a saRNA to activate CYP19A1 transcription in GCs
Our results demonstrated that miR-339 induces CYP19A1 transcription in sow GCs, which is consistent with one of the five main characteristics of saRNAs, that is, the activation of target transcription. We also observed that miR-339 did not activate the CYP19A1 PII promoter with a mutated MRE motif (Fig. 4a). These results suggest that miR-339 activates CYP19A1 transcription in sow GCs via its MRE motif within the PII promoter, which is in accordance with the second characteristic of saRNAs, that is, binding to target promoters.
Next, we investigated whether miR-339 conforms to other saRNA characteristics. In sow GCs cultured in vitro, miR-339 activated CYP19A1 transcription 48 h after treatment with miR-339 mimics, rather than 24 h for the RNAi mechanism of miRNAs (Fig. 4b), which is in accordance with the third characteristic of saRNA, that is, delayed effect. Similarly, CYP19A1 protein levels were significantly altered 48 h after treatment, but not at 24 h, in GCs (Fig. 4c, d). Notably, we detected the enrichment of AGO2, a core component of the RNA-induced transcriptional activation (RITA) complex , at the miR-339 MRE motif of the CYP19A1 PII promoter in sow GCs (Fig. 4e, f), which is in accordance with the fourth characteristic of saRNAs, that is, dependence on the RITA complex. Finally, Chromatin immunoprecipitation (ChIP) assays using specific antibodies showed that the enrichment of histone modifiers, including H3K4me3 and H3K9ac, increased at the miR-339 MRE motif of the CYP19A1 PII promoter in sow GCs treated with miR-339 mimics (Fig. 4g). This was in accordance with the fifth characteristic of saRNAs, that is, altering histone modifications. In summary, our data revealed that miR-339 conforms to the basic characteristics of an endogenous saRNA that activates CYP19A1 transcription in sow GCs.
NORSF suppresses E2 release through impairing miR-339/CYP19A1 axis
P450arom, encoded by CYP19A1 is necessary for catalyzing the final step of E2 biosynthesis. Therefore, we investigated the role of miR-339 in E2 release from sow GCs. ELISA assay showed that miR-339 induced E2 release by GCs (Fig. 5a). Furthermore, CYP19A1 depletion suppressed the E2 release induced by miR-339 (Fig. 5a), indicating that miR-339 induces E2 release by GCs via CYP19A1. Additionally, a significant positive correlation between sow follicular miR-339 levels and E2 concentration in the follicular fluid and follicular CYP19A1 levels was observed (Fig. 5b, c), suggesting that miR-339 is strongly involved in E2 release in sow GCs in vitro and in vivo.
Next, we investigated whether NORSF was also involved in E2 release by sow GCs. In sow GCs cultured in vitro, E2 concentration in the culture medium was significantly decreased by NORSF overexpression (Fig. 5d). Furthermore, CYP19A1 overexpression suppressed NORSF-induced E2 reduction (Fig. 5d), suggesting that NORSF reduces E2 release by GCs through suppressing CYP19A1 expression. Additionally, a significant negative correlation between follicular NORSF levels and E2 concentration in the follicular fluid, and follicular CYP19A1 levels was observed (Fig. 5e, f), suggesting that NORSF is also strongly involved in E2 release in sow GCs in vitro and in vivo.
Finally, we tested whether miR-339 mediated NORSF reduction of E2 release in sow GCs. Co-transfection experiments showed that miR-339 ameliorated the reduction in E2 release caused by NORSF (Fig. 5g), indicating that miR-339 mediates NORSF reduction of E2 release in GCs. Additionally, NORSF suppressed E2 release induced by miR-339 (Fig. 5h). Together, these data suggest that NORSF suppresses E2 release through impairing the miR-339/CYP19A1 axis, which further confirmed that NORSF is an endogenous ceRNA of miR-339 in controlling E2 release by sow GCs.
LncRNAs are well-known class of epigenetic factors that control gene expression at multiple levels (e.g. transcriptional, post-transcriptional, and post-translational levels) [32,33,34,35]. In the nucleus, lncRNAs mainly regulate gene transcription by recruiting various modulators (e.g. transcription factors, epigenetic regulators, and histone-modified complexes) to the regulatory regions such as enhancer, promoter, and introns near the 5'-end [36,37,38]. lncMREF, for instance, an important regulator of muscle regeneration, recruits SMARCA5 (a chromatin remodeler and an SWI/SNF protein) to the promoters of myogenic regulators (e.g. MyoD), thereby facilitating the genomic binding of the histone-modified complexes p300/CBP/H3K27ac to control the transcription of these myogenic regulators . A more recent study showed that an antisense lncRNA TGFB2-AS1 suppresses TGFB2 transcription in breast cancer cells through sequestering SMARCA4 (a SWI/SNF complex catalytic subunit) away from the TGFB2 promoter . Here, we showed a novel mechanism of action of nucleus-localized lncRNAs, by which they function as ceRNAs to sponge miRNAs in the nucleus of sow GCs. Furthermore, we used the nuclear lncRNA NORSF to demonstrate that it prevented miR-339 from interacting with the CYP19A1 PII promoter, thereby affecting CYP19A1 transcription in sow GCs. It would be reasonable to speculate that this ceRNA mode of nuclear lncRNAs is not unique to sow GCs, but crucial for nuclear lncRNAs in other cell types of other organisms including humans, to play a regulatory role. We counted 28217 lncRNAs confirmed by nucleoplasmic localization assays in 15 human cell types and showed that the proportion of lncRNAs that were more abundant in the nucleus was high in all cell types, ranging from 57.90% (H1.hESC) to 77.69% (SK.MEL.5 cells) (Additional file 2: Fig. S6). Furthermore, 34 putative miRNAs in the nucleus were predicted to interact with these nuclear lncRNAs in these cell types (Additional file 2: Fig. S7 and Additional file 1: Table S5). Next, we selected two well-known nuclear lncRNAs, MALAT1  and NEAT1 , to validate the ceRNA mechanism of nuclear lncRNAs using RNA pull-down. Both MALAT1 and NEAT1 were confirmed to be nuclear lncRNAs and sponged multiple nucleus-expressed miRNAs, including miR-24, miR-26, miR-29b and miR-373 in the human GC line KGN (Additional file 2: Fig. S8). Altogether, our findings uncover an underappreciated action model of nuclear lncRNAs, which not only enriches the mechanism of action of lncRNAs, but also establishes a new form of interaction between lncRNAs and miRNAs in the nucleus.
P450arom encoded by CYP19A1, catalyzes the final step of the E2 synthesis pathway. E2 secreted by target cells controls various biological processes of health and disease in organisms through classical genomic signaling, mediated by nuclear receptors including estrogen receptor α and β, and non-genomic signaling mediated by membrane receptors (i.e., G protein-coupled receptor 30, GPR30) [42,43,44]. Due to the importance of E2 in female reproduction, the regulation of its synthesis has always been a topic of interest, and P450arom and CYP19A1 have become important targets for regulating various normal physiological processes and treating diseases [45,46,47]. Several miRNAs targeting the CYP19A1 3'-UTR have been shown to inhibit its expression in normal and pathological cells [45, 48]. In this study, we revealed a new mode by which miRNAs activate CYP19A1 transcription and induce E2 secretion in sow GCs. Nucleus-expressed miR-339 acts as a saRNA to directly bind to the CYP19A1 promoter. saRNAs are a class of double-stranded ncRNAs with a length similar to that of miRNAs, and they have proven to be potential RNA-based drugs for RNA-based therapeutics. They include some coding mRNAs and other ncRNAs such as siRNAs, RNA aptamers, and RNA guides [49,50,51]. In 2008, miR-373 was the first miRNA that was demonstrated to act as an endogenous saRNA and directly interact with the promoters of target genes (including E-cadherin and CSDC2) to activate their transcription through an RNA activation (RNAa) mechanism . Subsequently, multiple endogenous RNAs have been identified in multiple species, including miR-155 in human umbilical vein endothelial cells , let-7i in mouse CD4 + T-cells , lin-4 in Caenorhabditis elegans hypodermal seam cells , and miR-23a in sow GCs . In summary, we identified, for the first time, an endogenous saRNA that induces E2 synthesis in GCs via the activation of CYP19A1 transcription. Our next step will be to evaluate whether miR-339 can serve as a small molecule non-hormone RNA drug for regulating sow reproduction, potentially replacing hormone drugs (such as GnRH) used for controlling follicular development and ovulation in sow production, and reducing the side effects of hormone drugs. Additionally, we also showed that the miR-339 sequence in mammals (including humans, mice, and pigs) is relatively conserved, and an MRE motif was identified in the human CYP19A1 promoter (Additional file 2: Fig. S9), indicating that miR-339 is a potential saRNA that targets CYP19A1 gene and controls E2 synthesis in humans. Furthermore, multiple MRE motifs of miR-339 were discovered in human LOC124906953 (Additional file 2: Fig. S10). This may have some significance in developing a potential small-molecule non-hormonal regulator to regulate female reproduction and improve female fertility in farm animals or treat estrogen-related diseases in humans. With the development of in vivo delivery systems, some saRNAs such as MTL-CEBPA  have been used in clinical practice to treat human diseases. In the future, saRNA therapy may be applicable to a wide range of diseases . In conclusion, we determined the subcellular localization profiles of lncRNAs in sow follicles and DELs during follicular atresia, and identified four nuclear lncRNAs in sow GCs. Notably, we identified a novel mechanism of action of nuclear lncRNAs, by which they act as ceRNAs to sponge miRNAs in the nucleus. Furthermore, we defined a new signaling pathway underlying the nuclear lncRNA NORSF that controls E2 release in GCs; NORSF sponges endogenous miR-339 in the nucleus of GCs, preventing it from binding to and activating the CYP19A1 promoter, thereby inhibiting CYP19A1 transcription and E2 synthesis (Fig. 5i).
Our findings uncover an underappreciated mode of action of nuclear lncRNAs. i.e., nuclear lncRNAs can act as ceRNAs to sponge miRNAs in the nucleus. Furthermore, we identified a novel signaling pathway of nuclear lncRNA NORSF/miR-339/CYP19A1 that controls E2 release in GCs. This study enriches our understanding of the action mechanisms of lncRNAs and provides a potential endogenous saRNA for controlling female reproduction.
For GC collection and culture, ovary samples of 210 Duroc-Landrace-Yorkshire sows with sexually mature and healthy were collected from the Lukou abattoir (Nanjing, China).
Online prediction of subcellular localization was performed using lncLocator (http://www.csbio.sjtu.edu.cn/bioinf/lncLocator/). The minimum free energy (MFE) of miRNA binding was evaluated using RNAhybrid (http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/). MRE motifs were detected using miRDB (http://mirdb.org/). The subcellular localization data for lncRNAs and miRNAs in human cells were downloaded from lncATLAS (https://lncatlas.crg.eu/) and RNALOCATE (http://www.rna-society.org/rna-locate/), respectively. LncBook 2.0 (https://ngdc.cncb.ac.cn/lncbook/) was used to predict the miRNAs that interact with lncRNAs. QTL-related data were obtained from the Pig QTL Database (https://www.animalgenome.org/cgi-bin/QTLdb/SS/index).
Collection of primary GCs and theca cells
Follicles with diameters ranging 3–5 mm were isolated from fresh ovaries using a sterilized scalpel. The follicular cavity was extracted with a syringe and centrifuged to collect GCs. For collecting theca cells, the follicular membrane was repeatedly scraped with forceps to remove mural GCs, then digested with 0.3 mg/mL collagenase I (#BS163, Biosharp, Guangzhou, China) at 37 °C for 1.5 h, filtered with a 100 μm cell sieve, and purified by Percoll gradients (#BS012, Biosharp).
Nuclear-cytoplasmic fractionation assays
Sow GCs were resuspended using a 4 °C lysis buffer (1 mM RNase inhibitor, 10 mM Tris, 1 mM NP-40, and 0.1 mM EDTA), and lysed at 4 °C for 10 min followed by centrifugation at 10,000 × g for 4 min. The supernatant was the cytoplasmic extract and the precipitate was the nuclear lysate. The precipitate was resuspended in 4 °C DEPC water (containing 1 mM RNase inhibitor) for 3 min, and centrifuged at 10,000 × g and 4 °C for 4 min; subsequently, the supernatant was removed to obtain the bottom nuclear extract. The TRIzol reagent (#RG-51001A; Angle Gene, Beijing, China) was used to isolate total RNA from the cytoplasm and nucleus. GAPDH and U6 were used as cytoplasmic and nuclear markers, respectively. Primers are listed in Additional file 1: Table S6.
RNA preparation and qPCR
TRIzol reagent (#RG-51001A, Angle Gene) was used to extract and purify total RNA. HiScript II Q Select RT SuperMix (#R232-01, Vazyme, Nanjing, China) and HiScript III 1st Strand cDNA Synthesis Kit (#R312-01, Vazyme) were used to reverse transcribe total RNA to cDNAs to quantify non-miRNAs genes and miRNAs, respectively. qPCR was executed using an AceQ qPCR SYBR Green Master Mix (#Q111-02, Vazyme), and the reaction parameters were as follows: hold stage 95 °C for 5 min; PCR stage 40 cycles at 95 °C for 10 s, 60 °C annealing for 30 s, and 95 °C for 15 s; melt curve stage 60 °C for 1 min and 95 °C for 1 s. 2−ΔΔCT method was used to estimate the relative transcript levels, and GAPDH (for non-miRNA genes) and U6 (for miRNAs) were the internal controls. Primers are listed in Additional file 1: Table S6.
Reporter vectors for lncRNAs or the CYP19A1 promoter containing the wild-type or mutated MRE motifs of the corresponding miRNAs were synthesized by Tsingke (Shanghai, China). For overexpression vector, cDNA fragment containing the full-length NORSF transcript was isolated from sow GCs, and inserted into the pcDNA3.1 vector (#V790-20, Invitrogen, USA). Primers are listed in Additional file 1: Table S6.
Cell culture and transfection
GCs were inoculated into cell culture plates filling with DMEM/F12 medium (containing 15% FBS and 1% PS) (#11320033, Gibco, CA, USA) and then transferred into in an incubator at 37 °C with 5% CO2. The human GC line KGN was cultured in the RPMI 1640 medium (#22400105, Gibco) containing 10% FBS and 1% PS. Once the cell density exceeded 80%, plasmids or oligonucleotides were transfected with the Lipofectamine 3000 (#L3000015, Invitrogen). All the oligonucleotides (Additional file 1: Table S7) were generated by GenePharma (Shanghai, China).
After 24 h of transfection, cells were collected, and detection of luciferase activity was performed using a DLR™ assay system (#E1910, Promega). The ratio of firefly and Renilla luciferase activities is taken as the relative luciferase activity.
RNA pull-down in vitro
20 µg of total RNA from the nucleus of GCs or KGN cells was incubated overnight with 5 µg of biotin-labeled probes at 4 °C. Streptavidin magnetic beads (#LSKMAGTO2, Merck Millipore, GER) were added and incubated for 2 h at 25 °C to pull down the lncRNA-RNA complexes. LncRNAs and miRNAs in the pull-down products were quantified by qPCR. Biotin-labeled probes for lncRNAs were synthesized by Sangon (Nanjing, China) and their sequences are shown in Additional file 1: Table S8.
RNA pull-down in vivo
Sow GCs were digested with trypsin (#25200056, Gibco) and cross-linked by shaking with 1% glutaraldehyde (#R20509, Shanghai Yuanye, China) at 25 °C for 10 min. After washing with PBS and subsequent lysis, GCs were exposed to biotin-labeled probes for NORSF and incubated at room temperature for 4 h. To pull down the NORSF-RNA complexes, streptavidin magnetic beads (#LSKMAGTO2) were added to the culture medium and incubated at 25 °C for 2 h. miR-339 in the pull-down products was quantified by qPCR.
To obtain the full-length sequence of the NORSF transcript, RACE assays were performed using the SMARTer® RACE 5′/3′ kit (#634858, Clontech Laboratories, Mountain View, USA). Briefly, 1 μg of high-integrity total RNA from sow GCs was used as a template to synthesize first-strand cDNA. Gene-specific primers were prepared as follows: 5′-CCG CCT CGG CTT CCT ACT AAA TCA CC-3′ (the reversed primer for 5′-RACE assay) and 5′-AGG GGG TGA TTT AGT AGG AAG CCG AGG-3′ (the forward primer for 3′-RACE assay). The 5′-RACE nested reverse primer is 5′-TCG CTT CCC TGT CAG AAT GTG-3′. The 3′-RACE nested forward primer is 5′-CAA CGC AGA GAA GAC CGA AAG-3′. PCR products were isolated using with a 1.5% agarose gel, and purified using a DNA Gel Extraction kit (#GE0101-200; TsingKe); subsequently, they were inserted into pClone007 vector (#TSV-007S; TsingKe) for sequencing.
Protein isolation and western blotting
RIPA lysis buffer (#AC23181, Bioworld, Nanjing, China) containing 0.1% PMSF (v/v) was used for isolating total protein from GCs. Proteins were denatured and placed on 12% SDS-PAGE gel loading wells and separated by electrophoresis, following which they were transferred to PVDF membranes, and blocked by 5% skim milk at room temperature for 1.5 h. Then, primary antibodies were used for incubation at 4 °C overnight, followed by incubation with secondary antibody at room temperature for 1 h. The primary antibodies used were anti-CYP19A1 (#A2161, ABclonal, 1:1000,), and anti-GAPDH (#TA802519, ORIGENE, 1:3000), and the secondary antibody was horseradish peroxidase-conjugated mouse anti-rabbit IgG (#D110065, Sangon Biotech, 1:1000). Raw images of the high-resolution blots were obtained using ImageQuant LAS-4000 (GE Healthcare, Chicago, IL, USA), and grayscale values were analyzed using ImageJ software.
ChIP assays were performed as previously described . Antibodies, including anti-H3K4me3 (#9751S, anti-H3K9ac (#9649S), and IgG antibody (#2985S) were purchased from Cell Signaling Technology (Danvers, MA, USA), and anti-AGO2 (#D121540) was purchased from Sangon. Enrichment of target DNA fragments was determined by qPCR and untreated chromatin was used as the NC and input control. Primers are listed in Additional file 1: Table S6.
E2 concentration determination
Follicular fluid was extracted using a syringe, and the supernatant was collected post centrifugation at 10,000 × g for 3 min. After treatment for 48 h, the GC culture medium was centrifuged at 10,000 × g for 3 min to collect the supernatant. The E2 concentration in the supernatant was measured by ELISA using a Detection Kit for Estrodial (E2) (#E9096-E2, North Biotech, Beijing, China), according to the manufacturer's instructions.
Experiments were performed in three biological replicates unless otherwise indicated, and statistically analyzed using SPSS v26.0 (IBM-SPSS, IL, USA) and GraphPad v8.0 (San Diego, CA, USA) software. Significance was assessed using the Student's t-test and one-way analysis of variance with the Tukey's Honest Significant Difference. Before conducting multiple comparisons, the normality of the data and the homogeneity of variance have been confirmed using SPSS v26.0 software (IBM-SPSS). The correlation coefficient was calculated using Pearson’s test.
Availability of data and materials
All data generated or analysed during this study are included in this published article and its supplementary information files. Additional information in support of the results of this study is also available from the corresponding author upon request.
competing endogenous RNA
small activating RNAs
non-coding RNA involved in sow fertility
long non-coding RNAs
differentially expressed lncRNAs
miRNA response elements
Rapid amplification of cDNA ends
quantitative trait locus
RNA-induced transcriptional activation
minimum free energy
Bartel DP. Metazoan microRNAs. Cell. 2018;173(1):20–51.
Herman AB, Tsitsipatis D, Gorospe M. Integrated lncRNA function upon genomic and epigenomic regulation. Mol Cell. 2022;82(12):2252–66.
Li L, Zhang X, Ren H, Huang X, Shen T, Tang W, et al. miR-23a/b-3p promotes hepatic lipid accumulation by regulating Srebp-1c and Fas. J Mol Endocrinol. 2021;68(1):35–49.
Peng M, Wang J, Tian Z, Zhang D, Jin H, Liu C, et al. Autophagy-mediated Mir6981 degradation exhibits CDKN1B promotion of PHLPP1 protein translation. Autophagy. 2019;15(9):1523–38.
Liao JY, Ma LM, Guo YH, Zhang YC, Zhou H, Shao P, et al. Deep sequencing of human nuclear and cytoplasmic small RNAs reveals an unexpectedly complex subcellular distribution of miRNAs and tRNA 3’ trailers. PLoS ONE. 2010;5(5): e10563.
Hwang HW, Wentzel EA, Mendell JT. A hexanucleotide element directs microRNA nuclear import. Science. 2007;315(5808):97–100.
Wang L, Du X, Li Q, Wu W, Pan Z, Li Q. miR-2337 induces TGF-beta1 production in granulosa cells by acting as an endogenous small activating RNA. Cell Death Discov. 2021;7(1):253.
Li H, Zhan J, Zhao Y, Fan J, Yuan S, Yin Z, et al. Identification of ncRNA-mediated functions of nucleus-localized miR-320 in cardiomyocytes. Mol Ther Nucleic Acids. 2020;19:132–43.
Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci U S A. 2008;105(5):1608–13.
Xiao M, Li J, Li W, Wang Y, Wu F, Xi Y, et al. MicroRNAs activate gene transcription epigenetically as an enhancer trigger. RNA Biol. 2017;14(10):1326–34.
Wang S, Li Y, Zeng Q, Yang L, Du X, Li Q. A mutation in endogenous saRNA miR-23a influences granulosa cells response to oxidative Stress. Antioxidants (Basel). 2022;11(6):1174.
Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol. 2021;220(2):e202009045.
Du X, Liu L, Li Q, Zhang L, Pan Z, Li Q. NORFA, long intergenic noncoding RNA, maintains sow fertility by inhibiting granulosa cell death. Commun Biol. 2020;3(1):131.
Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172(3):393–407.
Kayyar B, Ravikkumar AC, Bhaduri U, Rao M. Regulation of Sox8 through lncRNA Mrhl-mediated chromatin looping in mouse spermatogonia. Mol Cell Biol. 2022;42(5):e0047521.
Yong H, Wu G, Chen J, Liu X, Bai Y, Tang N, et al. lncRNA MALAT1 accelerates skeletal muscle cell apoptosis and inflammatory response in sepsis by decreasing BRCA1 expression by recruiting EZH2. Mol Ther Nucleic Acids. 2020;19:97–108.
Park MK, Zhang L, Min KW, Cho JH, Yeh CC, Moon H, et al. NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis. Cell Metab. 2021;33(12):2380-2397.e9.
Pan J, Xie Y, Li H, Li X, Chen J, Liu X, et al. mmu-lncRNA 121686/hsa-lncRNA 520657 induced by METTL3 drive the progression of AKI by targeting miR-328–5p/HtrA3 signaling axis. Mol Ther. 2022;30:3694–713.
Ji X, Liu Z, Gao J, Bing X, He D, Liu W, et al. N(6)-Methyladenosine-modified lncRNA LINREP promotes Glioblastoma progression by recruiting the PTBP1/HuR complex. Cell Death Differ. 2023;30(1):54–68.
Xu H, Jiang Y, Xu X, Su X, Liu Y, Ma Y, et al. Inducible degradation of lncRNA Sros1 promotes IFN-gamma-mediated activation of innate immune responses by stabilizing Stat1 mRNA. Nat Immunol. 2019;20(12):1621–30.
Liang L, Huan L, Wang J, Wu Y, Huang S, He X. LncRNA RP11–295G20.2 regulates hepatocellular carcinoma cell growth and autophagy by targeting PTEN to lysosomal degradation. Cell Discov. 2021;7(1):118.
Lin X, Dinglin X, Cao S, Zheng S, Wu C, Chen W, et al. Enhancer-driven lncRNA BDNF-AS induces endocrine resistance and malignant progression of breast cancer through the RNH1/TRIM21/mTOR cascade. Cell Rep. 2020;31(10):107753.
Elguindy MM, Mendell JT. NORAD-induced Pumilio phase separation is required for genome stability. Nature. 2021;595(7866):303–8.
Yao W, Du X, Zhang J, Wang Y, Wang M, Pan Z, et al. SMAD4-induced knockdown of the antisense long noncoding RNA BRE-AS contributes to granulosa cell apoptosis. Mol Ther Nucleic Acids. 2021;25:251–63.
Wang M, Wang Y, Yao W, Du X, Li Q. Lnc2300 is a cis-acting long noncoding RNA of CYP11A1 in ovarian granulosa cells. J Cell Physiol. 2022;237(11):4238–50.
Yao W, Pan Z, Du X, Zhang J, Liu H, Li Q. NORHA, a novel follicular atresia-related lncRNA, promotes porcine granulosa cell apoptosis via the miR-183-96-182 cluster and FoxO1 axis. J Anim Sci Biotechnol. 2021;12(1):103.
Du X, Li Q, Yang L, Zeng Q, Wang S, Li Q. Transcriptomic data analyses reveal that sow fertility-related lincRNA NORFA is essential for the normal states and functions of granulosa cells. Front Cell Dev Biol. 2021;9:610553.
Xu G, Hu Y, Yu D, Chen X, Li X, Duan S, et al. Discovery of differentially expressed microRNAs in porcine ovaries with smaller and larger litter size. Front Genet. 2022;13:762124.
Zhang X, Zhang L, Shang J, Tao Q, Tian M, Ma Y, et al. Combined microRNAome and transcriptome analysis of follicular phase and luteal phase in porcine ovaries. Reprod Domest Anim. 2019;54(7):1018–25.
Vaschetto LM. miRNA activation is an endogenous gene expression pathway. RNA Biol. 2018;15(6):826–8.
Portnoy V, Lin SH, Li KH, Burlingame A, Hu ZH, Li H, et al. saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription. Cell Res. 2016;26(3):320–35.
Ali MM, Akhade VS, Kosalai ST, Subhash S, Statello L, Meryet-Figuiere M, et al. PAN-cancer analysis of S-phase enriched lncRNAs identifies oncogenic drivers and biomarkers. Nat Commun. 2018;9(1):883.
Cao L, Zhang P, Li J, Wu M. LAST, a c-Myc-inducible long noncoding RNA, cooperates with CNBP to promote CCND1 mRNA stability in human cells. Elife. 2017;6:e30433.
Li Y, Liu X, Cui X, Tan Y, Wang Q, Wang Y, et al. LncRNA PRADX-mediated recruitment of PRC2/DDX5 complex suppresses UBXN1 expression and activates NF-kappaB activity, promoting tumorigenesis. Theranostics. 2021;11(9):4516–30.
Malakar P, Stein I, Saragovi A, Winkler R, Stern-Ginossar N, Berger M, et al. Long noncoding RNA MALAT1 regulates cancer glucose Metabolism by Enhancing mTOR-mediated translation of TCF7L2. Cancer Res. 2019;79(10):2480–93.
Lv W, Jiang W, Luo H, Tong Q, Niu X, Liu X, et al. Long noncoding RNA lncMREF promotes myogenic differentiation and muscle regeneration by interacting with the Smarca5/p300 complex. Nucleic Acids Res. 2022;50(18):10733–55.
Salerno D, Chiodo L, Alfano V, Floriot O, Cottone G, Paturel A, et al. Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription. Gut. 2020;69(11):2016–24.
Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010;329(5992):689–93.
Zhou C, Wang D, Li J, Wang Q, Wo L, Zhang X, et al. TGFB2-AS1 inhibits triple-negative breast cancer progression via interaction with SMARCA4 and regulating its targets TGFB2 and SOX2. Proc Natl Acad Sci U S A. 2022;119(39):e2117988119.
Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39(6):925–38.
Clemson CM, Hutchinson JN, Sara SA, Ensminger AW, Fox AH, Chess A, et al. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol Cell. 2009;33(6):717–26.
Gegenhuber B, Wu MV, Bronstein R, Tollkuhn J. Gene regulation by gonadal hormone receptors underlies brain sex differences. Nature. 2022;606(7912):153–9.
Harding AT, Goff MA, Froggatt HM, Lim JK, Heaton NS. GPER1 is required to protect fetal health from maternal inflammation. Science. 2021;371(6526):271–6.
Xu Y, Huangyang P, Wang Y, Xue L, Devericks E, Nguyen HG, et al. ERalpha is an RNA-binding protein sustaining tumor cell survival and drug resistance. Cell. 2021;184(20):5215-5229.e17.
Barwal TS, Sharma U, Bazala S, Singh I, Jain M, Prakash H, et al. MicroRNAs and long noncoding RNAs as novel therapeutic targets in estrogen receptor-positive breast and ovarian cancers. Int J Mol Sci. 2021;22(8):4072.
Magnani L, Frige G, Gadaleta RM, Corleone G, Fabris S, Kempe MH, et al. Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERalpha metastatic breast cancer. Nat Genet. 2017;49(3):444–50.
Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, et al. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer. 2020;1(4):382–93.
Li Q, Du X, Pan Z, Zhang L, Li Q. The transcription factor SMAD4 and miR-10b contribute to E2 release and cell apoptosis in ovarian granulosa cells by targeting CYP19A1. Mol Cell Endocrinol. 2018;476:84–95.
Wang F, Zuroske T, Watts JK. RNA therapeutics on the rise. Nat Rev Drug Discov. 2020;19(7):441–2.
Xiong Y, Ke R, Zhang Q, Lan W, Yuan W, Chan K, et al. Small activating RNA modulation of the G protein-coupled Receptor for cancer treatment. Adv Sci (Weinh). 2022;9(26):e2200562.
Zhu Y, Zhu L, Wang X, Jin H. RNA-based therapeutics: an overview and prospectus. Cell Death Dis. 2022;13(7):644.
Wang W, Geng J, Wu X, Zhang J, Zheng C, Rao H, et al. Preparation of a miR-155-activating nucleic acid nanoflower to study the molecular mechanism of miR-155 in inflammation. Mol Med. 2022;28(1):66.
Zhang Y, Fan M, Zhang X, Huang F, Wu K, Zhang J, et al. Cellular microRNAs up-regulate transcription via interaction with promoter TATA-box motifs. RNA. 2014;20(12):1878–89.
Turner MJ, Jiao AL, Slack FJ. Autoregulation of lin-4 microRNA transcription by RNA activation (RNAa) in C. elegans. Cell Cycle. 2014;13(5):772–81.
Sarker D, Plummer R, Meyer T, Sodergren MH, Basu B, Chee CE, et al. MTL-CEBPA, a small activating RNA therapeutic upregulating C/EBP-alpha, in patients with advanced liver cancer: A First-in-Human, Multicenter, Open-Label. Phase I Trial Clin Cancer Res. 2020;26(15):3936–46.
Khorkova O, Stahl J, Joji A, Volmar CH, Wahlestedt C. Amplifying gene expression with RNA-targeted therapeutics. Nat Rev Drug Discov. 2023;22(7):539–61.
Du X, Pan Z, Li Q, Liu H, Li Q. SMAD4 feedback regulates the canonical TGF-beta signaling pathway to control granulosa cell apoptosis. Cell Death Dis. 2018;9(2):151.
This work was financially supported by the National Natural Science Foundation of China (32272842) and the Qing Lan Project of Jiangsu Province (2020).
Ethics approval and consent to participate
Experiments involving sows were approved by the Animal Ethics Committee of Nanjing Agricultural University.
Consent for publication
Written informed consent for publication was obtained from all participants.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Table S1. LncRNAs in sow follicles. Table S2. Pedication of subcellular localization of sow follicular lncRNAs. Table S3. miRNAs potentially interacting with nuclear lncRNAs in sow GCs. Table S4. The relative binding activity between nuclear lncRNAs and their corresponding miRNAs. Table S5. miRNAs in the nucleus potentially interacting with nuclear lncRNAs. Table S6. Primers designed for reverse-transcription, qPCR, ChIP and plasmid construction. Table S7. Oligonucleotide sequences used in this study. Table S8. Biotin-labeled antisense probes.
Fig. S1. The RNA expression profile of five DELs in sow follicular theca cells and GCs. Fig. S2. Heatmap of miR-144, miR-378, miR-339 and miR-375 signals in sow follicles and GCs. Fig. S3. Other two potential MREs of miR-339 in LOC102164325. Fig. S4. Identification of lncRNA NORSF. Fig. S5. NORSF negatively regulates CYP19A1 expression in GCs. Fig. S6. Percentage of lncRNA nucleoplasm in multiple human cell types. Fig. S7. Interaction networks of lncRNAs and miRNAs in the nucleus of multiple human cell types. Fig. S8. Nuclear lncRNAs MALAT1 and NEAT1 interact with multiple miRNAs in the nucleus of human GCs. Fig. S9. miR-339 mature sequences are highly conserved among vertebrates. Fig. S10. The MRE motifs of miR-339 in human LOC124906953.
Table S1. Subcellular localization data. Table S2. Luciferase activity assay data. Table S3. RNA-pulldown in vitro data. Table S4. Quantitative real-time PCR raw data. Table S5. RNA-pulldown in vivo data. Table S6. E2 assay raw data. Table S7. Correlation analysis data.
Original image 1. Electrophoresis original images. Original image 2. RACE original image. Original image 3. Western blotting original images. Original image 4. CHIP original images.
About this article
Cite this article
Wang, M., Wang, Y., Yang, L. et al. Nuclear lncRNA NORSF reduces E2 release in granulosa cells by sponging the endogenous small activating RNA miR-339. BMC Biol 21, 221 (2023). https://doi.org/10.1186/s12915-023-01731-x